Clinical Trial Update: Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating IPH2101, a human monoclonal antibody, for activity, safety and pharmacology in patients with multiple myeloma. The study has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IPH2101

Snippet

Sponsor: Innate Pharma | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-24